d(GC) - Association of Biotechnology and Pharmacy

Current Trends in Biotechnology and Pharmacy
Vol. 6 (2) 229-240 April 2012, ISSN 0973-8916 (Print), 2230-7303 (Online)
Acknowledgement
The authors thank Dr Parvin Shariati for
critical reading of the manuscript.
Funding: We gratefully acknowledge the
financial grant received from the National Institute
of Genetic Engineering and Biotechnology (No.
298).
References
1. Baker, D.P., Lin, E.Y., Lin, K., Pellegrini, M.,
Petter, R.C., Chen, L.L., Arduini,
R.M.,Brickelmaier, M., Wen, D., Hess,
D.M., Chen, L., Grant, D., Whitty, A., Gill,
A., Lindner, D.J. and Pepinsky, R.B. (2006).
N-Terminally PEGylated Human Interferonβ-1a
with Improved Pharmacokinetic
Properties and in Vivo Efficacy in a
Melanoma Angiogenesis Model. Bioconj
Chem, 17(1):179-188.
2. Chevaliez, S. and Pawlotsky, J.M. (2007).
Interferon-based therapy of hepatitis C. Adv
Drug Del Rev, 59(12):1222-1241.
3. Souvignet, C., Lejeune, O. and Trepo, C.
(2007). Interferon-based treatment of
chronic hepatitis C. Biochimie, 89(6-7):894-
898.
4. Tayal, V. and Kalra, B.S. (2008). Cytokines
and anti-cytokines as therapeutics—an
update. Eur J Pharmaco, 579(1-3):1-12.
5. Esmata, G. and Abdel Fattah, S. (2009).
Evaluation of a novel pegylated interferon
alpha-2a in Egyptian patients with chronic
hepatitis C– genotype 4. Digest Liver Dis,
Suppl. 3:17-19.
6. Van Beers, M.M.C., Sauerborn, M., Gilli, F.,
Hermeling, S., Brinks, V., Schellekens, H.
and Jiskoo, W. (2010). Hybrid transgenic
immune tolerant mouse model for
assessing the breaking of B cell tolerance
Ahmad Abolhasani et al
238
by human interferon beta. J Immunol
Methods, 352(1-2):32-37.
7. Harris, J.M. and Chess, R.B. (2003). Effect
of pegylation on pharmaceuticals. Nat Rev
Drug Discov, 2(3):214-221.
8. Veronese, F.M. and Pasut, G. (2005).
PEGylation, successful approach to drug
delivery. Drug Discov Today, 10(21):1451-
1458.
9. Roberts, M.J., Bentley, M.D. and Harris,
J.M. (2002). Chemistry for peptide and
protein PEGylation. Adv Drug Deli Rev,
54(4):459-476.
10. Caliceti, P. and Veronese, F.M. (2003).
Pharmacokinetic and biodistribution
properties of poly(ethylene glycol)-protein
conjugates. Adv Drug Del Rev, 55:1261-
1277.
11. Na, D.H., Youn, Y.S., Lee, I.B., Park, E.J.,
Park, C.J. and Lee, K.C. (2006). Effect of
molecular size of PEGylated recombinant
human epidermal growth factor on the
biological activity and stability in rat wound
tissue. Pharm Dev Technol, 11:513-519.
12. Monkarsh, S.P., Ma, Y., Aglione, A., Bailon,
P., Ciolek, D., Debarbieri, B., Graves, M.
C., Hollfelder, K., Michel, H., Palleroni, A.,
Porter, J.E., Russoman, E., Roy, S. and
Pan, Y.C. (1997). Positional isomers of
monopegylated interferon alpha-2a:
isolation, characterization, and biological
activity. Anal Biochem, 247:434-440.
13. Bailon, P., Palleroni, A., Schaffer, C.A.,
Spence, C.L., Fung, W.J., Porter, J.E.,
Ehrlich, G.K., Pan, W., Xu, Z.X., Modi,
M.W., Farid, A., Berthold, W. and Graves,
M. (2001). Rational design of a potent, longlasting
form of interferon: a 40 kDa
branched polyethylene glycol conjugated
interferon alpha-2a for the treatment of
hepatitis C. Bioconj Chem, 12:195-202.